In the last trading session, 4.15 million Perspective Therapeutics Inc (AMEX:CATX) shares changed hands as the company’s beta touched 1.19. With the company’s per share price at $3.76 changed hands at $0.14 or 3.87% during last session, the market valuation stood at $279.10M. CATX’s last price was a discount, traded about -340.16% off its 52-week high of $16.55. The share price had its 52-week low at $1.60, which suggests the last value was 57.45% up since then. When we look at Perspective Therapeutics Inc’s average trading volume, we note the 10-day average is 1.62 million shares, with the 3-month average coming to 1.10 million.
Analysts gave the Perspective Therapeutics Inc (CATX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.14. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CATX as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Perspective Therapeutics Inc’s EPS for the current quarter is expected to be -0.29.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Instantly CATX was in green as seen at the end of in last trading. With action 8.67%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -60.63%, with the 5-day performance at 8.67% in the green. However, in the 30-day time frame, Perspective Therapeutics Inc (AMEX:CATX) is 45.74% up. Looking at the short shares, we see there were 5.62 million shares sold at short interest cover period of 4.06 days.
The consensus price target for the stock as assigned by Wall Street analysts is 21, meaning bulls need an upside of 82.1% from its current market value. According to analyst projections, CATX’s forecast low is 3 with 24 as the target high. To hit the forecast high, the stock’s price needs a -538.3% plunge from its current level, while the stock would need to tank 20.21% for it to hit the projected low.
Perspective Therapeutics Inc (CATX) estimates and forecasts
Year-over-year growth is forecast to reach -40.82% down from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 170.37k. 12 analysts are of the opinion that Perspective Therapeutics Inc’s revenue for the current quarter will be 162.91k. The company’s revenue for the corresponding quarters a year ago was 526k and 369k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -67.61%. The estimates for the next quarter sales put growth at -55.85%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.86%. The 2025 estimates are for Perspective Therapeutics Inc earnings to increase by 6.46%, but the outlook for the next 5-year period is at -1.94% per year.
CATX Dividends
Perspective Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-12.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.83% of Perspective Therapeutics Inc shares while 61.15% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 75.33%.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund . With 1.69 shares estimated at $6.37 million under it, the former controlled 2.28% of total outstanding shares. On the other hand, Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund held about 2.21% of the shares, roughly 1.64 shares worth around $6.18 million.
